{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:45:14Z","timestamp":1790851514302,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jhep.2022.06.010","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:16:21Z","timestamp":1655896581000},"page":"1422-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-3563","authenticated-orcid":false,"given":"Dominique","family":"Roulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.06.010_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.06.010_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.06.010_bib5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.06.010_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2022.06.010_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib8","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection","author":"Wedemeyer","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.06.010_bib9","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV coinfection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib10","first-page":"S291","article-title":"Safety and efficacy of bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic hepatitis delta: 24-week interim data of MYR204 Phase 2b study","volume":"75","author":"Asselah","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib11","first-page":"S294","article-title":"Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the phase 3 MYR301 study","volume":"75","author":"Wedemeyer","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib12","first-page":"S413A","article-title":"Treatment with bulevirtide improves patient reported outcomes in patients with chronic hepatitis delta (CHD): an interim exploratory analysis at week 24","volume":"74","author":"Wedemeyer","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib13","first-page":"S148A","article-title":"Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with bulevirtide in chronic HBV\/HDV co-infected patients: interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301)","volume":"74","author":"Allweiss","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib14","first-page":"S426A","article-title":"Rare cases of non-response in bulevirtide (BLV) treated patients from the MYR-204\/301 studies are not associated with the development of BLV resistance","volume":"74","author":"Hollnberger","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib15","first-page":"S16A","article-title":"Safety and efficacy of 2mg bulevirtide in patients with chronic HBV\/HDV co-infection. first real-world results (French early access program)","volume":"74","author":"De Ledinghen","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.06.010_bib17","first-page":"S1413A","article-title":"Early clinical and virological changes in HDV patients with advanced cirrhosis treated with bulevirtide monotherapy in a real-life setting","volume":"74","author":"Loglio","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib18","first-page":"S420A","article-title":"Efficacy of long-term treatment of chronic hepatitis D patients with bulevirtide \u2013 results of a \u201creal world\u201d study","volume":"74","author":"Binter","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.010_bib19","first-page":"S745","article-title":"First real-life experiences with 2 mg bulevirtide for the treatment of hepatitis delta-data from a tertiary reference centre in Germany","volume":"75","author":"Z\u00f6llner","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.010_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:14Z","timestamp":1759175294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822003737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0168827822003737"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}